All Articles
Cholangiocarcinoma (CCA) involves genetic heterogeneity, highlighting the need to identify new inherited variants, as discussed at the 3rd Annual CCA Summit in Session II, “Molecular Epidemiology of CCA.” Read More ›
On December 15, 2021, the FDA approved a new indication for abatacept (Orencia; Bristol Myers Squibb), a selective T-cell co-stimulation modulator, in combination with a calcineurin inhibitor and methotrexate, for the prophylaxis of acute graft-versus-host disease (GVHD) in adults and pediatric patients aged ≥2 years receiving hematopoietic stem-cell transplantation from a matched or 1 allele-mismatched unrelated donor. The FDA granted abatacept a priority review and breakthrough therapy and orphan drug designations. Read More ›
On December 3, 2021, the FDA approved a new indication for the PD-1 inhibitor pembrolizumab (Keytruda; Merck) for the adjuvant treatment of adult and pediatric patients (age ≥12 years) with stage IIB or IIC melanoma following complete resection. Read More ›
On November 30, 2021, the FDA approved the combination of subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro; Janssen Biotech) plus carfilzomib (Kyprolis; Amgen) and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy. Read More ›
On November 29, 2021, the FDA accelerated the approval of pafolacianine (Cytalux; On Target Laboratories), a novel fluorescent imaging agent, for adults with ovarian cancer as an adjunct for identifying inoperable malignant lesions. Read More ›
The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC. Read More ›
The results of a noninterventional, retrospective study showed that rituximab originator and the rituximab-abbs biosimilars yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs use resulting in cost-savings. Read More ›
Findings from modeling studies support adjuvant continuation of pertuzumab plus trastuzumab for patients achieving pathologic complete response among patients with high-risk, HER2-positive early breast cancer. Read More ›
Real-world outcomes from a retrospective, single-center study suggested that pegfilgrastim or its biosimilar pegfilgrastim-cbqv does not increase febrile neutropenia or delayed engraftment risk in patients with lymphoma and CLL and may be safe to use after administration of chemotherapy. Read More ›
The results of a retrospective, single-center analysis demonstrated that same-day pegfilgrastim or pegfilgrastim-cbqv was safe and effective in patients with diffuse large B-cell lymphoma who received a rituximab plus miniCHOP chemotherapy regimen, with no significant increase in febrile neutropenia or delayed engraftment. Read More ›